Takeda Vaccines Head: Peer Review Process For COVID-19 Vaccines Must Be 'Very Open'

The president of Takeda’s global vaccines business emphasizes the need to build trust and ensure that pharma is transparent about “what we will and will not know” at the time that COVID-19 vaccines are licensed.

COVID-19 Vaccine. Corona Virus SARS-CoV-2, 2019 nCoV virus destruction. A vaccine against coronavirus disease 2019. Breakthrough in the Creating of a COVID-19 Vaccine. — Transparency About COVID-19 Vaccine Data Vital, Says Takeda Executive • Source: Shutterstock

Public confidence and trust in COVID-19 vaccines will be paramount as potential candidates inch towards the market and pharma will need to be upfront on what is established and what is not clearly known at the time of product licensing, a top industry executive asserted at a recent healthcare summit.

Dr Rajeev Venkayya, president of Takeda Pharmaceutical Company Limited.’s global vaccine business unit, said that addressing the trust factor...